JWATM-204 is under clinical development by Eureka Therapeutics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JWATM-204’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JWATM-204 overview

JWATM-204 is under development for the treatment of hepatocellular carcinoma (HCC), non-small cell lung cancer and hepatoid adenocarcinoma of stomach. It is being developed based on ARTEMIS and E alpha technology platform. The drug candidate acts by targeting GPC3. The therapeutic candidate is a autologous T cells transduced with lentivirus encoding an ECT204 transgene.

Eureka Therapeutics overview

Eureka Therapeutics is a clinical-stage biotechnology company that focuses on the development of novel T-cell immunotherapies for the treatment of solid tumors and hematological diseases. Its pipeline comprises drug candidates for various indications such as adult and pediatric liver cancer, lung, breast and ovarian cancer, multiple solid tumors, ovarian cancer, multiple myeloma and B-cell leukemia and lymphoma. Its pipeline includes AFP, GPC3, ROR1, CD19, MUC16, WT1, BCMA, GPRC5D and CD19/CD22. Eureka Therapeutics utilizes its proprietary science platform ARTEMIS, which enables the discovery of fully-human antibodies against intracellular antigens via the MHC-peptide complex. Eureka Therapeutics is headquartered in Emeryville, California, the US.

For a complete picture of JWATM-204’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.